Advertisement

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

2014 ASH Annual Meeting

Advertisement

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797, “First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Patients,” presented by Sabina Chiaretti, MD, PhD, and abstract 798, “Nilotinib and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1–Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02),” presented by Oliver G. Ottman, MD.

Related Videos

Julie M. Vose, MD, MBA, FASCO

Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.

Hematologic Malignancies

Ayalew Tefferi, MD

Ayalew Tefferi, MD, on New Models of Prognostication for Myelofibrosis

Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 403, “A Compendium of Cytogenetic Abnormalities in Myelofibrosis: Molecular and Phenotypic Correlates in 826 Patients;” abstract 406, “Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis;” and abstract 405, “Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project.”

Bertrand Coiffier, MD, PhD

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “Rituximab Maintenance vs Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study,” presented by Steven Le Gouill, MD, PhD.

Hematologic Malignancies

Ayalew Tefferi, MD

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study.”

Hematologic Malignancies

Linda J. Burns, MD

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.

Advertisement

Advertisement

Jul

03

Today In Oncology

Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans

Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy

Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative

AACR Statement and Call to Action Concerning OMB Proposal

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Advertisement

© 2026 HSP News Service, L.L.C.